Drugs / Ad5-yCD/mutTKSR39rep-ADP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03029871 | Jan 2017 → Dec 2018 | non-small cell lung carcinoma | Benjamin Movsas, M.D. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-yCD/mutTKSR39rep-ADP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03029871 ↗ |
| Route | Other | “injected either transbronchially (central tumors) or percutaneously under computed tomography (CT)-guidance (peripheral tumors)” NCT03029871 ↗ |